A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
Public ClinicalTrials.gov record NCT03599713. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma (POD1UM-201)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma (MCC).
Study identification
- NCT ID
- NCT03599713
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 107 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 24, 2019
- Primary completion
- Jan 20, 2022
- Completion
- Jun 27, 2024
- Last update posted
- Aug 4, 2025
2019 – 2024
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford Cancer Institute | Palo Alto | California | 94304 | — |
| University of California San Francisco Comprehensive Cancer Center | San Francisco | California | 94143 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | — |
| Rush University | Chicago | Illinois | 60612 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40241 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | — |
| John Theurer Cancer Center, Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Rutgers Cancer Institute of Nj | New Brunswick | New Jersey | 08901 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| The Christ Hospital | Cincinnati | Ohio | 45219 | — |
| Upmc Cancercenter | Pittsburgh | Pennsylvania | 15232 | — |
| Inova Fairfax Hospital | Fairfax | Virginia | 22031 | — |
| University of Washington - Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
| West Virginia University Hospitals Inc | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03599713, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 4, 2025 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03599713 live on ClinicalTrials.gov.